Castleman Disease with Corey Casper, MD

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.